- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03841513
Minimally Invasive Burch Colposuspension to Reduce Occult Stress Incontinence (MICRO)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the United States it is estimated that 13% of women will undergo surgery for POP by age 80. In patients without symptoms of stress urinary incontinence (SUI), surgical correction of pelvic organ prolapse (POP) by itself can result in postoperative occult SUI. Two multicenter randomized trials of stress-continent women undergoing vaginal or open prolapse surgery showed lower rates of postoperative SUI if patients undergo concomitant anti-incontinence procedures. However, adverse outcomes vary based on the type of anti-incontinence procedure (open Burch colposuspension or retropubic midurethral sling) and route of surgery (open or vaginal), and therefore the preferred approach to address occult SUI is unknown.
Sacrocolpopexy is the gold standard surgical repair of pelvic organ prolapse of the apical compartment. The Burch colposuspension is a retropubic procedure in which the periurethral tissue of the anterior vagina is affixed to Cooper's ligament on either side using permanent suture bridges. In the Colpopexy and Urinary Reduction Efforts (CARE) trial patients without preoperative symptoms of SUI were randomized to receive or not to receive concomitant prophylactic Burch colposuspension at the time of abdominal sacrocolpopexy. At three months, the subjects who underwent the Burch procedure were found to have lower rates of SUI after surgery (33.6%) compared to the control group (57.4%). Furthermore, of patients who tested negative for SUI on preoperative urodynamic testing, 22.9 % of those who underwent the Burch procedure had SUI compared to 47.9% in the control group. Burch colposuspension did not increase the rate of urinary retention, urge incontinence, urinary urgency, urinary tract infection, intra or post-operative complications. The data in this trial supported the placement of prophylactic Burch colposuspension at the time of abdominal sacrocolpopexy.
Over the last decade, there has been a shift away from open routes of surgical access secondary to decreased morbidity and quicker recovery associated with minimally invasive procedures. As a result, open abdominal sacrocolpopexy with Burch colposuspension has fallen out of favor, and minimally invasive laparoscopic sacrocolpopexy is performed with greater frequency. Additionally, midurethral slings (MUS) have become the gold standard surgical procedure for the treatment of SUI and are performed more frequently than Burch colposuspension at the time of prolapse surgery. The Outcomes Following Vaginal Prolapse Repair and Midurethral Sling (OPUS) study examined the placement of prophylactic MUS at the time of vaginal prolapse surgery. Patients with MUS had lower rates of SUI than control group at 3 months (23.6% vs 49.4%) and at 12 months (27.3% vs 43%). However, unlike the CARE trial, patients with concomitant anti-incontinence procedure had higher rates of adverse events including bladder perforation (6.7% vs 0%), UTI (31.0% vs 18.3%), major bleeding (3.1% vs 0%), and incomplete bladder emptying at 6 weeks (3.7% vs 0%). In addition, MUS carries the risk of mesh erosion into the vagina or urinary tract.
By studying the addition of laparoscopic (including robotic) Burch colposuspension to laparoscopic sacrocolpopexy, the investigators anticipate optimizing surgical outcomes and minimizing complications for patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sylwia Clarke, BA
- Phone Number: 3126957748
- Email: sylwia.clarke@nm.org
Study Contact Backup
- Name: Akira Gillingham, MD
- Phone Number: 3124724023
- Email: akira.gillingham@nm.org
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Prentice Women's Hospital
-
Maywood, Illinois, United States, 60153
- Loyola University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- English or Spanish speaking and reading
- Symptomatic pelvic organ prolapse with any compartment at or beyond the hymen
- Stress-continent, as defined as response of "no" to question 17 of PFDI-20: "Do you usually experience urine leakage related to coughing, sneezing, or laughing?", as well as a negative empty supine stress test.
- Planning laparoscopic or robotic sacrocolpopexy, with or without hysterectomy
- Have completed childbearing
Exclusion Criteria:
- Adults unable to consent
- Pregnant women or patients desiring future pregnancy
- Patients undergoing uterine sparing surgery
- Individuals under age 18
- Prior procedure for stress urinary incontinence
- Prior retropubic surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, without the addition of a laparoscopic/robotic Burch colposuspension
|
|
Active Comparator: Laparoscopic Burch Colposuspension
Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, with the addition of a laparoscopic/robotic Burch colposuspension
|
The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stress Urinary Incontinence
Time Frame: 3 months following study intervention
|
Rate of Stress Urinary Incontinence, as defined as a participant satisfying one or more of the following:
|
3 months following study intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urinary Urgency Incontinence
Time Frame: 3 months following study intervention
|
Rate of Urgency Urinary Incontinence, as defined as a participant satisfying one or more of the following:
|
3 months following study intervention
|
Urinary Symptoms
Time Frame: at 2 weeks and again at 3 months following study intervention
|
Compare Urinary Symptoms utilizing the Pelvic Floor Distress Inventory 20 (PFDI-20), questions #15-20.
Participants respond to each question on a scale of 0 to 4, with higher scores indicating greater dysfunction.
The sum of scores is reported for this subscale, with a minimum score of 0 and maximum score of 24.
|
at 2 weeks and again at 3 months following study intervention
|
Rate of Urinary Retention
Time Frame: 2 weeks and 3 months following study intervention
|
Rate of Urinary Retention, defined as a post void residual greater than 150 mL obtained via straight catheterization
|
2 weeks and 3 months following study intervention
|
Rate of Urinary Tract Infection
Time Frame: 2 weeks and 3 months following study intervention
|
Rate of Urinary Tract Infection, defined as a positive urine culture obtained from a straight catheterized urine specimen, from participants with symptoms of urinary tract infection (fever, dysuria, urinary urgency, urinary frequency).
|
2 weeks and 3 months following study intervention
|
Pelvic Organ Prolapse Symptoms
Time Frame: at 2 weeks and again at 3 months following study intervention
|
Compare Pelvic Organ Prolapse Symptoms utilizing the Pelvic Floor Distress Inventory 20 (PFDI-20), questions #1-6.
Participants respond to each question on a scale of 0 to 4, with higher scores indicating greater dysfunction.
The sum of scores is reported for this subscale, with a minimum score of 0 and maximum score of 24.
|
at 2 weeks and again at 3 months following study intervention
|
Bowel Symptoms
Time Frame: at 2 weeks and again at 3 months following study intervention
|
Compare Bowel Symptoms utilizing the Pelvic Floor Distress Inventory 20 (PFDI-20), questions #7-14.
Participants respond to each question on a scale of 0 to 4, with higher scores indicating greater dysfunction.
The sum of scores is reported for this subscale, with a minimum score of 0 and maximum score of 32.
|
at 2 weeks and again at 3 months following study intervention
|
Sexual Function
Time Frame: 3 months following study intervention
|
Compare Sexual Function utilizing the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire 12 (PISQ-12).
Participants respond to each question on a scale of 0 to 4, with higher scores indicating greater dysfunction.
The sum of scores is reported for this subscale, with a minimum score of 0 and maximum score of 48.
|
3 months following study intervention
|
Rate of Surgical Complication
Time Frame: 2 weeks and 3 months following study intervention
|
Compare rate of intraoperative and short-term surgical complications, as defined by the Dindo classification system.
|
2 weeks and 3 months following study intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sarah A Collins, MD, Northwestern University
Publications and helpful links
General Publications
- Geller EJ, Siddiqui NY, Wu JM, Visco AG. Short-term outcomes of robotic sacrocolpopexy compared with abdominal sacrocolpopexy. Obstet Gynecol. 2008 Dec;112(6):1201-1206. doi: 10.1097/AOG.0b013e31818ce394.
- Wu JM, Matthews CA, Conover MM, Pate V, Jonsson Funk M. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol. 2014 Jun;123(6):1201-1206. doi: 10.1097/AOG.0000000000000286.
- Paraiso MF, Walters MD, Rackley RR, Melek S, Hugney C. Laparoscopic and abdominal sacral colpopexies: a comparative cohort study. Am J Obstet Gynecol. 2005 May;192(5):1752-8. doi: 10.1016/j.ajog.2004.11.051.
- Hsiao KC, Latchamsetty K, Govier FE, Kozlowski P, Kobashi KC. Comparison of laparoscopic and abdominal sacrocolpopexy for the treatment of vaginal vault prolapse. J Endourol. 2007 Aug;21(8):926-30. doi: 10.1089/end.2006.0381.
- Brubaker L, Cundiff GW, Fine P, Nygaard I, Richter HE, Visco AG, Zyczynski H, Brown MB, Weber AM; Pelvic Floor Disorders Network. Abdominal sacrocolpopexy with Burch colposuspension to reduce urinary stress incontinence. N Engl J Med. 2006 Apr 13;354(15):1557-66. doi: 10.1056/NEJMoa054208. Erratum In: N Engl J Med. 2016 Jun 9;374(23):2297-8.
- Wei JT, Nygaard I, Richter HE, Nager CW, Barber MD, Kenton K, Amundsen CL, Schaffer J, Meikle SF, Spino C; Pelvic Floor Disorders Network. A midurethral sling to reduce incontinence after vaginal prolapse repair. N Engl J Med. 2012 Jun 21;366(25):2358-67. doi: 10.1056/NEJMoa1111967.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Digestive System Diseases
- Urologic Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Gastrointestinal Diseases
- Urination Disorders
- Pathological Conditions, Anatomical
- Elimination Disorders
- Urinary Incontinence
- Prolapse
- Pelvic Organ Prolapse
- Intestinal Diseases
- Enuresis
- Urinary Incontinence, Stress
- Urinary Incontinence, Urge
Other Study ID Numbers
- STU00208016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sexual Dysfunction
-
Istanbul University - Cerrahpasa (IUC)CompletedSexual Dysfunction | Pregnancy Related | Postpartum Sexual DysfunctionTurkey
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompleted
-
Alza Corporation, DE, USACompletedSexual Dysfunction | Erectile Dysfunction | Ejaculation
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedSexual Dysfunction | Erectile DysfunctionFrance, Poland, United States, Belgium, Mexico, Malaysia, Canada, Taiwan, Korea, Republic of, Russian Federation, Argentina, Australia, United Kingdom
-
Royal Holloway UniversityNational Health Service, United KingdomCompletedSexual Dysfunction | Sexual Assault | Sex DisorderUnited Kingdom
-
Man Clinic for Andrology, Male Infertility and...UnknownSexual Dysfunction | Erectile Dysfunction | Premature EjaculationEgypt
-
University of UtahAcerus Pharmaceuticals CorporationWithdrawnSexual Dysfunction | Erectile DysfunctionUnited States
-
Assiut UniversityNot yet recruitingSexual Dysfunction
Clinical Trials on Laparoscopic Burch Colposuspension
-
Al-Azhar UniversityRecruitingStress Urinary Incontinence | Burch ColposuspentionEgypt
-
University Magna GraeciaWithdrawnStress Urinary IncontinenceItaly
-
Atatürk UniversityCompletedGenuine Stress IncontinenceTurkey
-
Damascus UniversityCompletedStress Urinary IncontinenceSyrian Arab Republic
-
Assiut UniversityNot yet recruitingTreatment of Female Stress Urinary Incontinence
-
Kanuni Sultan Suleyman Training and Research HospitalCompleted
-
Kanuni Sultan Suleyman Training and Research HospitalCompleted
-
University Of PerugiaCompletedUrinary Incontinence | Pelvic Organ ProlapseItaly
-
Ain Shams Maternity HospitalCompletedMed: Urinary Incontinence (Stress, Urge, Mixed)
-
Ain Shams UniversityCompleted